PT1363614E - Utilizacao de 2-amino-1-(4-hidroxi-3-metanossulfonamidofenil) etanol para o tratamento de incontinencia urinaria - Google Patents

Utilizacao de 2-amino-1-(4-hidroxi-3-metanossulfonamidofenil) etanol para o tratamento de incontinencia urinaria

Info

Publication number
PT1363614E
PT1363614E PT02710006T PT02710006T PT1363614E PT 1363614 E PT1363614 E PT 1363614E PT 02710006 T PT02710006 T PT 02710006T PT 02710006 T PT02710006 T PT 02710006T PT 1363614 E PT1363614 E PT 1363614E
Authority
PT
Portugal
Prior art keywords
methanosulfonamidofenyl
hydroxy
ethanol
amino
treatment
Prior art date
Application number
PT02710006T
Other languages
English (en)
Inventor
Franz Esser
Pouzet Pascale
Kitagawa Hisato
Ishiguro Naoki
Muramatsu Ikunobu
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PT1363614E publication Critical patent/PT1363614E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/35Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT02710006T 2001-02-01 2002-01-15 Utilizacao de 2-amino-1-(4-hidroxi-3-metanossulfonamidofenil) etanol para o tratamento de incontinencia urinaria PT1363614E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10104369A DE10104369A1 (de) 2001-02-01 2001-02-01 Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz

Publications (1)

Publication Number Publication Date
PT1363614E true PT1363614E (pt) 2005-06-30

Family

ID=7672382

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02710006T PT1363614E (pt) 2001-02-01 2002-01-15 Utilizacao de 2-amino-1-(4-hidroxi-3-metanossulfonamidofenil) etanol para o tratamento de incontinencia urinaria

Country Status (26)

Country Link
EP (1) EP1363614B1 (pt)
JP (1) JP2004517158A (pt)
KR (1) KR20030075173A (pt)
CN (1) CN1489459A (pt)
AR (1) AR035778A1 (pt)
AT (1) ATE293966T1 (pt)
BG (1) BG108033A (pt)
BR (1) BR0206854A (pt)
CA (1) CA2434565A1 (pt)
CZ (1) CZ20032097A3 (pt)
DE (2) DE10104369A1 (pt)
DK (1) DK1363614T3 (pt)
EA (1) EA200300789A1 (pt)
EC (1) ECSP034684A (pt)
EE (1) EE200300357A (pt)
ES (1) ES2240708T3 (pt)
HU (1) HUP0302752A2 (pt)
IL (1) IL156730A0 (pt)
MX (1) MXPA03006816A (pt)
NO (1) NO20033428L (pt)
PL (1) PL361731A1 (pt)
PT (1) PT1363614E (pt)
SK (1) SK9772003A3 (pt)
UY (1) UY27145A1 (pt)
WO (1) WO2002060421A2 (pt)
ZA (1) ZA200305201B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
JP6486359B2 (ja) * 2013-08-19 2019-03-20 タリス バイオメディカル エルエルシー 多ユニット薬物送達デバイス及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US341584A (en) * 1886-05-11 Device foe
FR148F (pt) * 1962-01-24
DE69113466T2 (de) * 1990-02-07 1996-03-14 Nippon Shinyaku Co Ltd Sulfonanilidderivat und arzneimittel.
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
EP0835107A1 (en) * 1995-06-02 1998-04-15 Synaptic Pharmaceutical Corporation The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
WO2000010557A1 (fr) * 1998-08-25 2000-03-02 Nippon Shinyaku Co.,Ltd. Preparations solides stabilisees

Also Published As

Publication number Publication date
UY27145A1 (es) 2002-08-30
CN1489459A (zh) 2004-04-14
MXPA03006816A (es) 2004-05-14
DE60203882D1 (de) 2005-06-02
DK1363614T3 (da) 2005-05-30
HUP0302752A2 (hu) 2003-11-28
PL361731A1 (en) 2004-10-04
NO20033428D0 (no) 2003-07-31
BG108033A (en) 2004-12-30
NO20033428L (no) 2003-09-30
EA200300789A1 (ru) 2004-02-26
WO2002060421A3 (en) 2002-12-19
CZ20032097A3 (cs) 2003-12-17
ES2240708T3 (es) 2005-10-16
JP2004517158A (ja) 2004-06-10
WO2002060421A2 (en) 2002-08-08
ZA200305201B (en) 2004-05-17
EE200300357A (et) 2003-10-15
EP1363614B1 (en) 2005-04-27
ECSP034684A (es) 2003-08-29
DE10104369A1 (de) 2002-08-08
BR0206854A (pt) 2004-01-13
SK9772003A3 (sk) 2005-03-04
EP1363614A2 (en) 2003-11-26
KR20030075173A (ko) 2003-09-22
CA2434565A1 (en) 2002-08-08
DE60203882T2 (de) 2006-02-02
IL156730A0 (en) 2004-02-08
AR035778A1 (es) 2004-07-14
ATE293966T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
BR0317690B8 (pt) dispositivo vaginal para incontinÊncia urinÁria.
NO20035609L (no) Fremgangsmate for kontinuerlig naftabehandling
BR0314016B1 (pt) dispositivo para incontinÊncia urinÁria intravaginal.
BR0105828B1 (pt) dispositivo para locomoÇço de deficientes fÍsicos.
BR0315138B1 (pt) aplicador de dispositivo para incontinÊncia vaginal.
DK1432701T3 (da) Heterocycliske forbindelser til anvendelse ved behandlingen af lidelser i urinvejene
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
ITMI20010733A0 (it) Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
PT1206436E (pt) Retinoides para o tratamento de enfisema
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PT1413305E (pt) Derivados aril (ou heteroaril) azolilcabrinol para o tratamento de incontinencia urinaria
AU2003288019A1 (en) Use of an alkyl ether of hydroxystilbene for the treatment of dry skin
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
PT1363614E (pt) Utilizacao de 2-amino-1-(4-hidroxi-3-metanossulfonamidofenil) etanol para o tratamento de incontinencia urinaria
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
ZA200405173B (en) 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence.
ES1047068Y (es) Juego de cuerpos lastrados para el tratamiento de la incontinencia urinaria.
EE200300177A (et) m-aminofenüüliminoimidasolidiinderivaadid uriinipidamatuse raviks
NO20033368D0 (no) Nye alkyl-fenylimino-imidazolidin-derivater for behandling av urin-inkontinens
PT1383512E (pt) Utilizacao de sucralfato para o tratamento de erosao cervical
BR8103426Y1 (pt) absorvente para incontinência urinária masculina.
ES1054336Y (es) "ducha ortopedica para discapacitados"
ITMI20000147A0 (it) Procedimeto per il trattamento di fanghi
AU2002334310A1 (en) 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders